Abstract 1882
Background
Due to the rarity and heterogeneity of recurrent and/or metastatic head and neck non-squamous cell carcinoma (R/M HN non-SCC), no standard chemotherapy for this condition has yet been established. This multicenter phase II trial evaluated the efficacy and safety of docetaxel and cisplatin combination (DC) in R/M HN non-SCC.
Methods
Eligibility criteria were R/M HN non-SCC; progressive disease within the last 6 months; no prior systemic therapy, or interval of at least 24 weeks since the last induction chemotherapy or chemoradiotherapy with curative intent; measurable disease; and ECOG performance status of 0 or 1. Patients (pts) received docetaxel (75 mg/m2 on day 1) and cisplatin (75 mg/m2 on day 1), repeated every 21 days for 6 cycles. The primary endpoint was objective response rate (ORR).
Results
From Nov 2012 to Oct 2016, a total of 23 pts were enrolled, characterized as 15 females, median age 57 years (range, 32-76), and 96% metastatic. Among 22 evaluable pts, ORR was 45.5% (95% confidential interval [CI], 24.4-67.8%), and the lower bound of the 95% CI of 24.4% exceeded the predefined hypothesis of 10%. ORRs according to primary tumor site and histology are shown in the table below. With a median follow-up period of 18.8 months, median progression-free survival and overall survival were 6.7 and 20.1 months, respectively. Grade 3/4 adverse events included neutropenia (91%), febrile neutropenia (FN) (39%), anemia (22%), appetite loss (17%), and fatigue (13%). The FN rate was significantly lower in the pts with prophylactic antibiotics (57 vs 11%, P = 0.04). No treatment-related deaths were observed.Table: 1066P
Objective response rates according to primary tumor site and histology
| Adenoid cystic carcinoma | Aadenocarcinoma, not otherwise specified | Salivary duct carcinoma | Sebaceous carcinoma | Mucoepidermoid carcinoma | NUT midline carcinoma | Acinic cell carcinoma | Total | |
|---|---|---|---|---|---|---|---|---|
| Salivary gland | 2/4 | 2/3 | 2/3 | 0/1 | 6/11 | |||
| Nasal cavity/paranasal sinus | 1/3 | 1/3 | ||||||
| Ocular | 0/1 | 2/2* | 2/3 | |||||
| Oral cavity/lip | 1/1 | 0/1 | 1/2 | |||||
| Oropharynx | 0/1 | 0/1 | 0/2 | |||||
| Ear | 0/1 | 0/1 | ||||||
| Total | 3/10 | 2/4 | 2/3 | 2/2 | 1/1 | 0/1 | 0/1 | 10/22 |
complete response
Conclusions
This phase II study of DC met its primary endpoint. This DC regimen is effective and represents a new treatment option in the treatment of progressive R/M HN non-SCC, although prophylactic antibiotics for FN should be considered.
Clinical trial identification
UMIN000008333.
Legal entity responsible for the study
Kobe University Hospital.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5720 - Evaluation of stemness and proliferation of human breast cancer stem cells (ALDH+) supplemented with heat-activated TGF-beta1 in the secretomes of stem cells from human exfoliated deciduous teeth (SHED)
Presenter: Septelia Wanandi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4844 - Estrogen-related receptor _ as a potential molecular target for endometrial cancer therapy
Presenter: TETSUYA KOKABU
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1200 - Good tolerability and limited target-specific tissue distribution of an anti-L1CAM antibody administered to cynomolgus monkey indicates favorable safety profile of L1CAM-targeting therapies
Presenter: Jacques Gaudreault
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2905 - Pharmacokinetic drug-drug interaction between mitotane and etoposide in the treatment of adrenocortical carcinoma
Presenter: Anne Jouinot
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2597 - Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): final results from the prospective, observational CORRELATE study
Presenter: Juan Manuel O'Connor
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2663 - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase 3b PRECONNECT study
Presenter: Julien Taieb
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1670 - Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study
Presenter: Takeshi Kawakami
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1088 - Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD
Presenter: thomas Aparicio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2548 - Prospective Evaluation of Regorafenib Dose Escalation Strategy with Low Starting Dose in Patients with Colorectal Cancer
Presenter: Toshiki Masuishi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3244 - Regorafenib for metastatic colorectal carcinoma: a registry-based analysis
Presenter: Katerina Kopeckova
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract